Clinical Trial Update: QOL-Stereotactic RadioSurgery, Temozolomide + Erlotinib-Rx of 1-3 Brain Metastases in NSCLC [Phase 2]

View source ↗

Summary

This is a Phase 2 trial update indicating withdrawal of a study evaluating QOL-Stereotactic Radiosurgery with temozolomide and erlotinib for 1-3 brain metastase…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tarceva (erlotinib)
• Temodar (Temozolomide)

Snippet

Sponsor: University of Medicine and Dentistry of New Jersey | Conditions: Lung Cancer, Metastatic Cancer | Phase 2 | Status: WITHDRAWN